Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 186 700 KRW 1.85% Market Closed
Market Cap: 43.1T KRW

Celltrion Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Celltrion Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Free Cash Flow
â‚©559.3B
CAGR 3-Years
168%
CAGR 5-Years
34%
CAGR 10-Years
59%
SK Bioscience Co Ltd
KRX:302440
Free Cash Flow
-â‚©300.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Free Cash Flow
-â‚©30.3B
CAGR 3-Years
-18%
CAGR 5-Years
5%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Free Cash Flow
â‚©109.4B
CAGR 3-Years
38%
CAGR 5-Years
51%
CAGR 10-Years
49%
Alteogen Inc
KOSDAQ:196170
Free Cash Flow
â‚©66.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
ABL Bio Inc
KOSDAQ:298380
Free Cash Flow
-â‚©44.8B
CAGR 3-Years
-1%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Celltrion Inc. stands as a significant player in the global biopharmaceutical industry, rooted in the heart of South Korea's bustling innovation scene. Founded in 2002 by Seo Jung-Jin, the company initially carved its niche in the development of biosimilars, which are near-identical versions of original biological drugs whose patents have expired. With rapid advancements in biotechnology, Celltrion has well-positioned itself to tap into the expanding market for affordable and accessible biologic treatments. At the core of its operation is its cutting-edge production facilities equipped with high-tech fermentation and purification processes necessary for manufacturing these complex medicines. This foundational expertise has allowed Celltrion to pioneer some of the world's first monoclonal antibody biosimilars, including those for autoimmune diseases and oncological conditions, thereby cementing its reputation as a forerunner in global biosimilar development. The company’s revenue model is intricately tied to its production capabilities and strategic partnerships. By leveraging its advanced manufacturing infrastructure, Celltrion not only produces its own line of biosimilars but also collaborates with global pharmaceutical companies to license and distribute its products worldwide. Such partnerships have enabled Celltrion to penetrate markets across Europe, the Americas, and Asia, with its biosimilars gaining regulatory approval in many regions. Furthermore, Celltrion’s business is not limited to biosimilars; it is actively investing in novel biologics and innovative delivery systems. This diversification strategy underscores its commitment to sustainable growth and reducing dependence on any single product line, ultimately fostering a robust pipeline that promises to meet the healthcare industry's evolving demands.

Intrinsic Value
166 825.7 KRW
Overvaluation 11%
Intrinsic Value
Price

See Also

What is Celltrion Inc's Free Cash Flow?
Free Cash Flow
559.3B KRW

Based on the financial report for Jun 30, 2025, Celltrion Inc's Free Cash Flow amounts to 559.3B KRW.

What is Celltrion Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
59%

Over the last year, the Free Cash Flow growth was 583%. The average annual Free Cash Flow growth rates for Celltrion Inc have been 168% over the past three years , 34% over the past five years , and 59% over the past ten years .

Back to Top